ネタルスジルの新興薬剤に関する洞察と市場予測：2032年

Aerie Pharmaceuticals（Alconが買収）が開発中のネタルスジルは、FECDによる角膜浮腫を治療する点眼薬です。Rhoキナーゼ阻害薬として作用し、海綿体網膜からの房水の流出を増加させることにより眼圧を低下させます。しかし、正確なメカニズムは不明です。

Rhoキナーゼ阻害剤は、前臨床モデルにおいて角膜内皮細胞の接着を促進し、増殖を促進し、アポトーシスを抑制することが示されており、角膜内皮脱落症の治療に役立つ可能性があります。

当レポートでは、主要7ヶ国におけるネタルスジル市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 FECDに対するネタルスジルの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ネタルスジル市場評価

• FECDに対するネタルスジルの市場見通し
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるFECDに対するネタルスジルの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Netarsudil, Clinical Trial Description, 2023
• Table 2: Netarsudil, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Netarsudil Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Netarsudil Market Size in the US, in USD million (2019-2032)
• Table 7: Netarsudil Market Size in Germany, in USD million (2019-2032)
• Table 8: Netarsudil Market Size in France, in USD million (2019-2032)
• Table 9: Netarsudil Market Size in Italy, in USD million (2019-2032)
• Table 10: Netarsudil Market Size in Spain, in USD million (2019-2032)
• Table 11: Netarsudil Market Size in the UK, in USD million (2019-2032)
• Table 12: Netarsudil Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Netarsudil Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Netarsudil Market Size in the United States, USD million (2019-2032)
• Figure 3: Netarsudil Market Size in Germany, USD million (2019-2032)
• Figure 4: Netarsudil Market Size in France, USD million (2019-2032)
• Figure 5: Netarsudil Market Size in Italy, USD million (2019-2032)
• Figure 6: Netarsudil Market Size in Spain, USD million (2019-2032)
• Figure 7: Netarsudil Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Netarsudil Market Size in Japan, USD million (2019-2032)

“"Netarsudil Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about netarsudil for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets. A detailed picture of the netarsudil for FECD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the netarsudil for FECD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the netarsudil market forecast analysis for FECD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in FECD.

Drug Summary:

Netarsudil, being developed by Aerie Pharmaceuticals (acquired by Alcon), is an ophthalmic solution for treating corneal edema due to FECD. It acts as a Rho kinase inhibitor thereby reducing intraocular pressure (IOP) by increasing the outflow of aqueous humor through the trabecular meshwork route. However, the exact mechanism is unknown.

Rho Kinase inhibitors have been shown to promote adhesion, enhance proliferation and inhibit apoptosis of corneal-endothelial cells in pre-clinical models and may have potential benefits for the treatment of corneal endothelial decompensation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the netarsudil description, mechanism of action, dosage and administration, research and development activities in Fuchs Endothelial Corneal Dystrophy (FECD).
• Elaborated details on netarsudil regulatory milestones and other development activities have been provided in this report.
• The report also highlights the netarsudil research and development activities in FECD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around netarsudil.
• The report contains forecasted sales of netarsudil for FECD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for FECD.
• The report also features the SWOT analysis with analyst views for netarsudil in FECD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Netarsudil Analytical Perspective by DelveInsight

• In-depth Netarsudil Market Assessment

This report provides a detailed market assessment of netarsudil for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Netarsudil Clinical Assessment

The report provides the clinical trials information of netarsudil for FECD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Fuchs Endothelial Corneal Dystrophy (FECD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence netarsudil dominance.
• Other emerging products for FECD are expected to give tough market competition to netarsudil and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of netarsudil in FECD.
• Our in-depth analysis of the forecasted sales data of netarsudil from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the netarsudil in FECD.

Key Questions

• What is the product type, route of administration and mechanism of action of netarsudil?
• What is the clinical trial status of the study related to netarsudil in Fuchs Endothelial Corneal Dystrophy (FECD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the netarsudil development?
• What are the key designations that have been granted to netarsudil for FECD?
• What is the forecasted market scenario of netarsudil for FECD?
• What are the forecasted sales of netarsudil in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to netarsudil for FECD?
• Which are the late-stage emerging therapies under development for the treatment of FECD?

Table of Contents

1. Report Introduction

2. Netarsudil Overview in FECD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Netarsudil Market Assessment

• 5.1. Market Outlook of Netarsudil in FECD
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Netarsudil in the 7MM for FECD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Netarsudil in the United States for FECD
  • 5.3.2. Market Size of Netarsudil in Germany for FECD
  • 5.3.3. Market Size of Netarsudil in France for FECD
  • 5.3.4. Market Size of Netarsudil in Italy for FECD
  • 5.3.5. Market Size of Netarsudil in Spain for FECD
  • 5.3.6. Market Size of Netarsudil in the United Kingdom for FECD
  • 5.3.7. Market Size of Netarsudil in Japan for FECD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options